Target intelligence / Profile preview

VEGF Family (VEGF-A, VEGF-B, VEGF-C, PlGF) (VEGF/PlGF Family)

Target
VEGF/PlGF Family
Molecular classification
Growth factor, Secreted ligand, Members of the PDGF/VEGF family, Ligands for VEGFR-1 (Flt-1), Ligands for VEGFR-2 (KDR/Flk-1), Ligands for VEGFR-3 (Flt-4)
01

Overview

The VEGF family (VEGF-A, VEGF-B, VEGF-C, PlGF) comprises secreted proteins that control vascular and lymphatic formation and remodeling. These growth factors bind and activate VEGF receptors (VEGFR-1, VEGFR-2, and VEGFR-3), triggering intracellular signaling cascades essential for angiogenesis, lymphangiogenesis, and vascular permeability. Dysregulation is implicated in cancer, inflammatory processes, and vascular diseases. Multiple approved drugs neutralize these proteins or block their receptors, and their inhibition poses notable but manageable safety risks.

Other names
VEGF-AVEGF-BVEGF-CPlGFVEGFvascular permeability factorplacental growth factorVEGF-B167VEGF-B186
02

Mechanism of action

Ligand neutralization (monoclonal antibody binds VEGF-A/PlGF, blocks receptor interaction), decoy receptor binding (fused VEGFR extracellular domains that sequester VEGF), inhibition of receptor tyrosine kinase activity (small molecules block VEGFR signaling), RNA aptamer binding (direct inhibition of VEGF-A).

03

Biological functions

Angiogenesis (VEGF-A, PlGF, VEGF-B)Lymphangiogenesis (VEGF-C)Vascular permeability (VEGF-A)Embryonic blood vessel development (VEGF-B)Vasculogenesis (PlGF)Cellular migrationCellular proliferation
04

Disease associations

Cancer (tumor angiogenesis)Cancer (metastasis)Inflammation (wound healing)Inflammation (ischemia)Cardiovascular disease (atherosclerosis)Cardiovascular disease (myocardial ischemia)Eye diseases (age-related macular degeneration)Eye diseases (diabetic retinopathy)Lymphatic disordersTissue ischemiaTissue repair pathologies
05

Safety considerations

Impaired wound healingHypertensionProteinuria and renal toxicityHemorrhage and thromboembolic riskCardiac dysfunctionGI perforation
06

Interacting drugs

Bevacizumab

6 more in the full profile.

07

Biomarkers

Circulating VEGF-A levelsTissue immunohistochemistry for VEGF-A/VEGF-C in tumorsPlGF serum levelsVEGFR expression profiling

Beyond the preview

Go deeper on VEGF Family (VEGF-A, VEGF-B, VEGF-C, PlGF) (VEGF/PlGF Family).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on VEGF Family (VEGF-A, VEGF-B, VEGF-C, PlGF) (VEGF/PlGF Family).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call